

***In utero* smoke exposure and impaired response to inhaled corticosteroids in children with asthma**

Robyn T. Cohen, MD, MPH,^a Benjamin A. Raby, MD, CM, MPH,^{a,b,c} Kristel Van Steen, PhD,^d Anne L. Fuhlbrigge, MD, MS,^{a,b,c} Juan C. Celedón, MD, DrPH,^{a,b,c} Bernard A. Rosner, PhD,^a Robert C. Strunk, MD,^e Robert S. Zeiger, MD, PhD,^{f,g} and Scott T. Weiss, MD, MS,^{a,c} for the Childhood Asthma Management Program Research Group *Boston, Mass, Liège, Belgium, St Louis, Mo, and San Diego, Calif*

Background: Few studies have examined the effects of *in utero* smoke exposure (IUS) on lung function in children with asthma, and there are no published data on the impact of IUS on treatment outcomes in children with asthma.

Objectives: To explore whether IUS exposure is associated with increased airway responsiveness among children with asthma and whether IUS modifies the response to treatment with inhaled corticosteroids (ICSs).

Methods: To assess the impact of parent-reported IUS exposure on airway responsiveness in childhood asthma, we performed a repeated-measures analysis of methacholine PC₂₀ data from the Childhood Asthma Management Program, a 4-year, multicenter, randomized, double-masked, placebo-controlled trial of 1041 children age 5 to 12 years comparing the long-term efficacy of ICS with mast cell stabilizing agents or placebo.

Results: Although improvement was seen in both groups, children with asthma and IUS exposure had on average 26% less of an improvement in airway responsiveness over time

compared with unexposed children ($P = .01$). Moreover, while children who were not exposed to IUS who received budesonide experienced substantial improvement in PC₂₀ compared with untreated children (1.25-fold increase; 95% CI, 1.03-1.50; $P = .02$), the beneficial effects of budesonide were attenuated among children with a history of IUS exposure (1.04-fold increase, 95% CI, 0.65-1.68; $P = .88$).

Conclusion: *In utero* smoke exposure reduces age-related improvements in airway responsiveness among children with asthma. Moreover, IUS appears to blunt the beneficial effects of ICS use on airways responsiveness. These results emphasize the importance of preventing this exposure through smoking cessation counseling efforts with pregnant women. (J Allergy Clin Immunol 2010;■■■:■■■-■■■.)

Key words: Asthma, *in utero* smoke exposure, airway responsiveness, inhaled corticosteroids

From ^athe Channing Laboratory, ^bthe Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, ^cHarvard Medical School, Boston; ^dMontefiore Institute, Bioinformatics, University of Liège; ^ethe Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital; and ^fthe Department of Pediatrics, University of California—San Diego, and ^gAllergy Department, Kaiser Permanente, San Diego.

The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. B.A.R. is a recipient of a Mentored Clinical Scientist Development Award from NHLBI/NIH (K08 HL074193).

Disclosure of potential conflict of interest: R. T. Cohen has received research support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the Philadelphia Health and Education Corp, and Trustees of the Alumni/ae Association of the Women's Medical College of Pennsylvania. B. A. Raby is an editor for UpToDate. A. L. Fuhlbrigge was previously a consultant, advisory board member, and speaker for Merck and is currently a consultant for GlaxoSmithKline. B. A. Rosner has received research support from the National Institutes of Health. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, MedImmune, and Merck and has received research support (through Kaiser Permanente) from AstraZeneca, Aerocrine, Genentech, GlaxoSmithKline, and Merck. The rest of the authors have declared that they have no conflict of interest.

Received for publication January 4, 2010; revised May 25, 2010; accepted for publication June 11, 2010.

Reprint requests: Robyn T. Cohen, MD, MPH, Department of Pediatrics, Drexel University College of Medicine and St Christopher's Hospital for Children, 3601 A Street, Philadelphia, PA 19134. E-mail: robyn.cohen@drexelmed.edu. 0091-6749/\$36.00

© 2010 American Academy of Allergy, Asthma & Immunology
doi:10.1016/j.jaci.2010.06.016

Exposure to cigarette smoke during fetal development is harmful to children. *In utero* smoke exposure (IUS) increases the risk of obstetric complications (eg, abruptio placentae, premature birth, intrauterine growth restriction) and sudden infant death syndrome. Prenatal smoke exposure has also been shown to be associated with decreased cognitive development and school performance and an increased risk of behavioral and psychiatric difficulties.^{1,2}

There is compelling evidence that IUS results in significant respiratory sequelae as well, which can manifest early in life. Reductions in forced expiratory flows, tidal flow-volume ratios, and respiratory compliance have been observed in healthy newborns of mothers who smoked during pregnancy.³⁻⁵ Similar reductions in peak expiratory flows⁶ and small airway flows^{6,7} have been observed in school-age children, suggesting a long-term impact of IUS on pulmonary function. An analysis of pooled data from several international studies demonstrated an increased risk of poor lung function among children exposed to IUS, even after adjustment for current exposure to environmental tobacco smoke (ETS).⁷ IUS has also been associated with an increased risk of recurrent wheeze⁸ and incident asthma at school age⁹⁻¹¹ and in adulthood.¹²

In contrast with numerous population-based studies about the effects of IUS on lung function in infants and children, only 1 study has specifically examined the effects of IUS on the lung function of children already diagnosed with asthma. Data from 5933 participants in the California Children's Health Study showed that children and adolescents who were diagnosed with

Abbreviations used

CAMP: Childhood Asthma Management Program
 ETS: Environmental tobacco smoke
 FVC: Forced vital capacity
 IUS: *In utero* smoke exposure

asthma before age 5 years and who had been exposed to IUS had greater deficits in FEV₁/forced vital capacity (FVC), forced expiratory flow at 25% to 75% of FVC, and forced expiratory flow at 25% to 75% of FVC/FVC than unexposed children with asthma.¹³ Importantly, there are no published data regarding the impact of IUS on airway responsiveness or treatment outcomes in children with asthma.

Here we assess the relationship between IUS and subsequent airway responsiveness in a cohort of children age 5 to 12 years with well established mild to moderate persistent asthma who participated in a randomized, placebo-controlled trial that evaluated the long-term efficacy and safety of inhaled anti-inflammatory medications. This study design provides a unique opportunity to explore whether *in utero* tobacco smoke exposure attenuated the beneficial effect of inhaled steroids that was seen overall among study participants.¹⁴ We demonstrate that IUS has a substantial detrimental impact on responsiveness to inhaled corticosteroid therapy.

METHODS

Details of the Childhood Asthma Management Program (CAMP) trial have been described elsewhere.^{15,16} Briefly, CAMP is a multicenter, randomized, double-masked clinical trial to compare the long-term effectiveness and safety of 3 inhaled treatments for asthma: budesonide, nedocromil, and placebo. CAMP enrolled 1041 children age 5 to 12 years with mild-moderate asthma at 8 clinical centers between December 1993 and September 1995. Asthma was defined by the presence of asthma symptoms or the use of an inhaled bronchodilator at least twice per week or use of a daily asthma medication for the 6 months before the screening interview. All participants had increased airway responsiveness to methacholine (PC₂₀ ≤ 12.5 mg/mL) at study entry. Children were excluded if they had severe asthma or other active sinopulmonary disease. Each parent or guardian signed a consent form, and each participant 7 years of age and older signed an assent form approved by each clinical center's institutional review board.

Information regarding *in utero* tobacco smoke exposure was obtained during the baseline medical interview, which was nearly always completed by the mothers of CAMP participants. Children were considered to have IUS exposure if respondents answered affirmatively to the question, "Did this child's mother smoke while she was pregnant with this child?" Information about current ETS exposure was obtained during follow-up interviews with the question, "Do any caretakers of the child currently smoke cigarettes?"

Of the 1041 participating children, 311 were assigned to receive budesonide (200 µg twice daily; Turbuhaler; AstraZeneca, Westborough, MA), 312 were assigned to receive nedocromil sodium (8 mg twice daily; Tilade; Rhone-Poulenc Rorer, Collegeville, Pa), and 418 were assigned to receive a matching placebo. Albuterol (two 90-µg actuations from a metered-dose inhaler; Ventolin; Glaxo Wellcome, Research Triangle Park, NC) was used as needed for symptoms of asthma and to prevent exercised-induced bronchospasm.

Spirometry, both before and after the administration of a bronchodilator, was performed twice per year. A methacholine challenge was performed at baseline (after a 28-day washout period during which no participants were taking inhaled steroids) and then annually during the treatment phase, using the Wright nebulizer-tidal breathing technique, at least 4 hours after the last use of a short-acting bronchodilator and at least 24 hours after the last use of a long-acting bronchodilator. After a control diluent challenge, nine doubling

doses of methacholine were nebulized for 2 minutes each at 5-minute intervals. Spirometry was performed 90 seconds after each challenge until FEV₁ had fallen by 20% or more. Methacholine challenge was not performed within 28 days of an upper respiratory tract infection or the use of prednisone for exacerbations of asthma. The child's height and weight were recorded at every visit.

The distribution of PC₂₀ at each visit was skewed, with a long right tail. PC₂₀ was therefore natural log-transformed for all regression analyses. Longitudinal regression was performed to test the association between IUS and PC₂₀ before and after adjustment for potential confounders and to distinguish interindividual changes in PC₂₀ from within-subject change. We developed random-effects models using SAS PROC MIXED (SAS Institute, Cary, NC), related log-transformed PC₂₀ to the aforementioned effects, and accounted for associated time observations within a patient. Components of variability were a random intercept supplemented with a serial correlation. Longitudinal analysis with PROC MIXED was also used to test the effect of treatment group assignment (budesonide vs nedocromil or placebo) on PC₂₀ after stratification by IUS status.

RESULTS

All children with asthma in CAMP (n = 1041) had baseline methacholine challenge tests. Methacholine challenge testing was completed for 92%, 90%, 85%, and 82% of the cohort at 8, 20, 32, and 44 months after randomization, respectively. Baseline characteristics were generally similar between children with and without methacholine challenge data at 44 months. Children who were missing PC₂₀ measurements were more likely to have been recruited from 3 of the clinical sites (Albuquerque, Boston, Seattle), to have come from families with lower household income, and to have mothers with a history of either asthma or smoking during pregnancy. Baseline median natural logarithm PC₂₀ was similar between groups (Wilcoxon rank sum *P* values > .30).¹⁷

Of the 1041 participants, 5 subjects were missing IUS data and were therefore excluded from analyses. One hundred fifty (14%) had reported exposure to IUS (Table I). One hundred nine children (73% of those exposed) had IUS exposure during all 3 trimesters. Exposed children were more likely to have mothers without any college education (*P* < .001) and subsequent exposure to ETS than children not exposed to IUS (*P* < .001). The characteristics of the 2 groups at baseline, including spirometry and PC₂₀, were otherwise similar.

A repeated-measures analysis of methacholine PC₂₀ data collected over the 44 months of the CAMP clinical trial found, as previously reported,¹⁷ that parental history of asthma, total serum IgE, and lung function were associated with increased airway responsiveness, both at baseline (before treatment randomization) and over the 44 months of observation. Although current ETS exposure was associated with increased airway responsiveness at baseline, this relationship did not remain significant over time. Baseline PC₂₀ (before the initiation of treatment) did not differ between children who were and were not exposed to IUS (*P* = .89), and there was improvement in the median PC₂₀ in all treatment groups over time, regardless of IUS exposure. However, children in all treatment groups exposed to IUS demonstrated significantly less improvement in airway hyperresponsiveness than children who were not exposed, demonstrating a mean change in PC₂₀ that was 26% lower than that of nonexposed children (95% CI, 6% to 42%; *P* = .01). Similar results were obtained after adjustment for environmental tobacco exposure, height, and lung function (both at baseline and over the course of the trial), suggesting an independent effect of IUS on airway responsiveness

TABLE I. Characteristics of the study population*

Variable	Not exposed to <i>in utero</i> smoke (n = 886), no. (%)	Exposed to <i>in utero</i> smoke (n = 150), no. (%)	P value†
Sex, female	356 (40.2)	61 (40.7)	.91
Current ETS exposure			
8 Months postrandomization	177 (20.6)	101 (69.7)	<.0001
20 Months postrandomization	170 (20.1)	106 (73.6)	<.0001
32 Months postrandomization	160 (19.1)	95 (68.8)	<.0001
44 Months postrandomization	152 (18.2)	93 (69.9)	<.0001
Maternal history of asthma	232 (26.8)	30 (20.8)	.13
Paternal history of asthma	182 (21.6)	26 (20.0)	.67
Assigned to treatment group			.26
Budesonide	271 (30.6)	39/150 (26)	
Nedocromil/placebo	615 (69.4)	111/150 (74)	
Clinic site			.41
Albuquerque	103 (11.6)	17 (11.3)	
Baltimore	106 (12.0)	22 (14.7)	
Boston	105 (11.9)	19 (12.7)	
Denver	118 (13.3)	26 (17.3)	
San Diego	111 (12.5)	11 (7.3)	
Seattle	119 (13.4)	21 (14.0)	
St Louis	119 (13.4)	14 (9.3)	
Toronto	105 (11.9)	20 (13.3)	
Income <\$30,000	186 (21.9)	55 (37.9)	<.0001
Maternal education: > some college	756 (85.4)	95 (63.3)	<.0001
Median (interquartile range) values at baseline			
	No IUS	IUS	P value‡
Age at study entrance (y)	8.9 (3.4)	8.7 (3.4)	.39
FEV ₁ (% predicted)	94 (18)	95 (16)	.52
FEV ₁ /FVC	81 (11)	81 (9)	.14
Serum total IgE (IU)	460 (1057)	368 (921)	.05
PC ₂₀ (mg/mL)	1.1 (2.3)	1.1 (1.8)	.89
Height (cm)	132.8 (20.7)	131.2 (21.3)	.13

*Numbers and percentages may vary because of missing values for some variables.

† χ^2 P value.

‡Kruskal-Wallis P value.

(Table II). Although there were significant differences in household income and maternal education level between those exposed and unexposed to IUS, inclusion of these terms in multivariable models did not change the results; these terms were not included in final models.

As previously reported,^{14,17} children randomized to budesonide (an inhaled corticosteroid) demonstrated a substantial improvement in airway hyperresponsiveness over the course of the CAMP clinical trial compared with children randomized to either inhaled nedocromil or placebo. The association between IUS and greater airway hyperresponsiveness after but not before (at baseline) treatment randomization suggested that IUS may alter responsiveness to inhaled corticosteroids—the primary recommended treatment for persistent asthma.¹⁸ To explore this possibility, we assessed the impact of inhaled corticosteroids on airway responsiveness in an analysis stratified by IUS status. Whereas children who had no history of IUS derived a substantial benefit from budesonide treatment on airway responsiveness over time compared with nedocromil or placebo (25% increase, ie, improvement, in PC₂₀ from baseline; 95% CI 3%-50%; $P = .02$; Table III; Fig 1, A), children exposed to IUS had a severely blunted response to inhaled budesonide, with no discernible difference in improvement in PC₂₀ compared with nedocromil or placebo ($P = .88$; Table III; Fig 1, B). This effect persisted after adjustment for height, current lung function, and current ETS

TABLE II. Effects of IUS on postrandomization repeated measures of methacholine PC₂₀*†

Variable	Fold-change in PC ₂₀ (95% CI)†	P value
IUS (yes)	0.74 (0.58-0.94)	.01
Age (per year increase)	0.91 (0.86-0.95)	.04
Female sex (yes)	0.94 (0.79-1.10)	.40
Maternal history of asthma (yes)	0.83 (0.69-0.99)	.04
Paternal history of asthma (yes)	0.80 (0.66-0.97)	.02
ETS exposure (yes)*	0.99 (0.87-1.13)	.89
Treatment with budesonide (yes)	1.26 (1.06-1.50)	.01
FEV ₁ (per L increase)*	2.90 (2.44-3.46)	<.001
Height (per cm increase)*	0.98 (0.97-0.99)	<.001
Total serum IgE at baseline (per log10 IU increase)	0.45 (0.40-0.51)	<.001

Boldface values highlight the exposure of interest in our multivariable model.

*Measured at each study visit

†Fold-change in methacholine PC₂₀ as determined from exponential of β -estimate derived from multivariate linear regression, adjusting for other covariates in table.

‡Multivariable mixed models assumed an unstructured, autoregressive covariance and were also adjusted for study center.

exposure. We attempted to test the statistical significance of this differential effect of IUS on treatment response by repeating the original longitudinal analysis with the inclusion of an interaction term for treatment arm by IUS over time. The 3-way interaction

TABLE III. The impact of IUS exposure on responsiveness of methacholine PC₂₀ to treatment with inhaled budesonide||§

	IUS = No (n = 886)		IUS = Yes (n = 150)	
	Fold-change in PC ₂₀ (95% CI)‡	P value	Fold-change in PC ₂₀ (95% CI)‡	P value
Treatment with budesonide (yes)	1.25 (1.03-1.50)	.02	1.04 (0.65-1.68)	.88
FEV ₁ (per L increase)*	2.97 (2.46-3.59)	<.001	3.16 (1.98-5.02)	<.001
Height (per cm increase)*	0.97 (0.97-0.98)	<.001	0.96 (0.94-0.98)	<.001
Maternal history of asthma (yes)	0.82 (0.68-1.00)	.05	0.82 (0.48-1.4)	.64
Paternal history of asthma (yes)	0.72 (0.59-0.89)	.003	1.72 (1.02-2.92)	.07
Total serum IgE at baseline (per log ₁₀ IU increase)	0.43 (.030-0.63)	<.001	0.44 (0.32-0.61)	<.001
Clinic of origin		<.001†		.05†
Current ETS exposure (yes)	0.96 (0.83-1.11)	.65	0.96 (0.70-1.32)	.81


*Assessed at each study visit.

†F test P value.

‡Fold-change in methacholine PC₂₀ as determined from exponential of β -estimate derived from multivariate linear regression, adjusting for other covariates in table.

§Multivariable mixed models assumed an unstructured, autoregressive covariance.

||P value for 3-way interaction IUS*treatment with budesonide*time = .78. Model also includes interaction terms for IUS*treatment with budesonide, IUS*time, treatment with budesonide*time.

**FIG 1.** Effects on longitudinal methacholine PC₂₀ attributable to treatment with either budesonide or nedocromil/placebo postrandomization among (A) those without IUS and (B) those with IUS.

term of IUS*treatment group*time was significant (P value test for interaction, .02), although on inclusion of second-order terms (IUS*treatment, IUS*time, and treatment*time), this interaction term was no longer significant ($P = .78$), most likely because of the small number of subjects exposed to IUS who were randomized to the budesonide treatment arm ($n = 39$).

DISCUSSION

Inhaled corticosteroids are both commonly prescribed and efficacious for the treatment of asthma in children and adults. They have been shown to reduce airway responsiveness, asthma symptoms, need for breakthrough bronchodilator therapy, and exacerbation rates.^{14,19} However, there is considerable between-subject variability in clinical response to inhaled corticosteroids, including patients who manifest partial to substantial steroid resistance necessitating escalation of treatment dose.²⁰ Though there is evidence that a proportion of this variability has a genetic basis,²¹ other factors may be at play.

We here demonstrate for the first time that *in utero* tobacco smoke exposure may be an important determinant of responsiveness to inhaled corticosteroids. In our study, a history of IUS conferred near complete resistance to inhaled corticosteroid treatment, whereas children without such exposure demonstrated marked improvements. We also found a differential effect for paternal history of asthma between IUS-exposed and unexposed groups ($P = .005$). The importance of a paternal history of asthma on airway responsiveness has been reported in a previous article.¹⁷ Our current findings may be indicative of additional gene-by-environment effects; however, we are unable to examine this further in multivariable models because of sample size limitations.

Although the precise mechanisms underlying our findings are not yet known, the observation that airway responsiveness was similar between exposure groups before treatment but different thereafter suggests that the initiation of therapy with inhaled corticosteroids can differentiate clinical subgroups of children with asthma and underlying differences in lung structure that result from IUS. Studies of animal and human lung morphology support the notion that IUS causes structural changes in the lung. Sekhon et al²² have demonstrated that nicotine crosses the placenta and induces increased connective tissue expression within pulmonary vessels, resulting in notable impairment of lung function in newborn rhesus monkeys.²³ This group also found decreased alveolar airspace complexity and increased expression of nicotinic cholinergic receptors in airway epithelial cells, smooth muscle cells, and blood vessels in rhesus monkeys exposed to IUS. Nicotinic receptor expression was strongly correlated with increased collagen deposition in cartilaginous airways of these monkeys.²⁴ Prenatal nicotine exposure stimulates branching morphogenesis in murine lung explants, potentially

contributing to dysynaptic lung growth.²⁵ Postmortem studies in infants provide further evidence of the adverse effects of IUS on airway morphology. In a study of airway morphology in 38 infants who died from sudden infant death syndrome (half of whom were exposed to IUS), IUS was associated with increased inner airway wall thickness.²⁶ Similar studies have demonstrated an association between IUS and increased alveolar attachments distance,²⁷ a finding previously associated with reduced elastic recoil.²⁸

In addition to affecting lung structure, the effects of *in utero* tobacco smoke exposure on airway responsiveness may be a result of changes in airway smooth muscle physiology. Singh et al²⁹ demonstrated airway hyperresponsiveness in mice exposed to IUS that was not a result of differences in airway inflammation. Lavage fluid from these mice contained decreased levels of cyclic adenosine monophosphate—a potent airway smooth muscle relaxant—compared with IUS-unexposed mice. IUS-induced reductions in cyclic adenosine monophosphate could also influence response to inhaled corticosteroids in other ways, because cyclic adenosine monophosphate is an inhibitor of T-cell chemotaxis and may inhibit airway remodeling. It is also possible that the impact of cigarette smoke exposure on subsequent glucocorticoid responsiveness is indirectly mediated through increased susceptibility to lower respiratory tract infections in early life, which in turn contribute to airway remodeling, as proposed by Piedimonte³⁰ and others.³¹ Testing of this hypothesis in prospective birth cohorts with accurate assessments of early-life respiratory infections would help clarify this possibility.

The CAMP study was primarily designed to assess the primary effects of inhaled anti-inflammatory medication on lung function in children with asthma, not to evaluate specifically the effects of *in utero* exposures on treatment response. Thus, it is important to consider whether our findings could be explained by design-related biases. Three major issues of concern are statistical power, exposure misclassification, and residual confounding by both current ETS exposure and differences in adherence between IUS-exposed and unexposed children. Of the 150 children with reported IUS, only 39 were randomized to budesonide. Therefore, we first assessed whether our inability to detect improvement in airway responsiveness among children exposed to IUS was a result of low statistical power. This is unlikely because although low power may limit our ability to detect a statistical difference between treatment arms, the observed mean difference in response in the exposed group (as reflected in the fold changes in PC₂₀ in Table III) was a fraction of that observed in the unexposed group. Furthermore, there was a protocol in place for open-label rescue use of inhaled beclomethasone. By the end of the clinical trial, both the nedocromil and placebo groups had significantly more rescue use of beclomethasone than the budesonide groups.¹⁴ This disproportionate use of supplemental ICS by the nonbudesonide groups would be expected to reduce the likelihood that we would detect a difference between treatment arms. With regard to exposure misclassification, we recognize that IUS designation was based on self-report. Though several studies support the higher accuracy of self-reported smoking during pregnancy compared with other detection methods (ie, serum cotinine,³² urine cotinine,^{33,34} and exhaled carbon monoxide³⁵), others suggest that self-report underestimates the true prevalence of smoking during pregnancy.³⁶⁻³⁸ It is therefore possible that exposure misclassification was underestimated, particularly given that questionnaires were administered 5 to 12 years postpartum. If so,

we may have underestimated the true effect of IUS on airway responsiveness.

Could our results be caused by residual confounding by ETS exposure rather than primary *in utero* effects? Because the majority of subjects with a history of IUS also report current exposure to cigarette smoke, it is not possible to exclude this possibility fully. However, in our study, models that do not adjust for IUS fail to demonstrate a significant association of current exposure with PC₂₀ ($P = .89$ in multivariable models adjusted for IUS and $.38$ in multivariable models not adjusted for IUS). Although this is somewhat reassuring, we recognize that confirmation of our findings in other populations with sufficient numbers of subjects with *in utero*, but not current, smoke exposure is required. We also note that we were unable to explore a possible dose-response relationship because for most IUS-exposed subjects, the exposure was present for all 3 trimesters. An additional outstanding question is whether children exposed to IUS were also more likely to be noncompliant with daily inhaled corticosteroids. Unfortunately, we do not have sufficient data available to us to compare adherence between the IUS-exposed and unexposed groups. However, we note that we did not see significant differences between those subjects exposed to ETS and those without such exposure with regard to treatment effect on airway hyperresponsiveness. One might expect that adherence would similarly be a confounder among that subgroup as well.

In summary, this study demonstrates for the first time that IUS has the potential to attenuate the beneficial effect of inhaled corticosteroids on airways responsiveness in children with asthma. These results provide further reasons for physicians to emphasize the importance of preventing this exposure through smoking cessation counseling efforts with pregnant women.

Further study is needed to define the mechanism of action of this exposure as well as to elucidate the effect of IUS on other measures of airway responsiveness including response to bronchodilators.

MEMBERS OF THE CAMP RESEARCH GROUP

Clinical centers

ASTHMA, Inc, Seattle, Wash: Gail G. Shapiro, MD (Director); Thomas R. DuHamel, PhD (Co-Director); Mary V. Lasley, MD (Co-Director); Tamara Chinn, MSN, ARNP (Coordinator). Michele Hinatsu, MSN, ARNP; Clifton T. Furukawa, MD; Leonard C. Altman, MD; Frank S. Virant, MD; Paul V. Williams, MD; Michael S. Kennedy, MD; Jonathan W. Becker, MD; Grace White. C. Warren Bierman, MD (1992-1997); Dan Crawford, RN (1996-2002); Heather Eliassen, BA (1996-1999); Babi Hammond (1996-1999); Dominick A. Minotti, MD (1992-2003); Chris Reagan (1992-2003); Marian Sharpe, RN (1992-1994); Timothy G. Wighton, PhD (1994-1998).

Brigham & Women's Hospital, Boston, Mass: Scott Weiss, MD, MS (Director); Anne Fuhlbrigge, MD (Principal Investigator); Anne Plunkett, NP, MS (Coordinator). Nancy Madden, RN, BSN; Peter Barrant, MD; Christine Darcy; Kelly Thompson, MD. Walter Torda, MD (Co-Investigator Director, 1993-2003); Martha Tata, RN (1993-2002); Sally Babigian, RN (1997-1999); Linda Benson (1998-2004); Jose Caicedo (1998-1999); Tatum Calder (1998-2001); Anthony DeFilippo (1994-2000); Cindy Dorsainvil (1998-2001); Julie Erickson (1998-1999); Phoebe Fulton (1997); Mary Grace, RN (1994-1996); Jennifer Gilbert (1997-1998); Dirk Greineder, MD (1993-2000); Stephanie Haynes (1993-1998);

Margaret Higham, MD (1996-1998); Deborah Jakubowski (1999); Susan Kelleher (1993-1997); Jay Koslof, PhD (1993-1995); Dana Mandel (1996-1998); Patricia Martin (2001-2003); Agnes Martinez (1994-1997); Jean McAuliffe (1994-1995); Erika Nakamoto (2002-2004); Paola Pacella (1993-1998); Paula Parks (1993-1995); Johanna Sagarin (1998-1999); Kay Seligsohn, PhD (1995-2004); Susan Swords (2003-2005); Meghan Syring (1998-2001); June Traylor, MSN, RN (1996-1998); Melissa Van Horn, PhD (1996-1999); Carolyn Wells, RN (1993-1995); Ann Whitman, RN (1994-1996).

The Hospital for Sick Children, Toronto, Ontario, Canada: Ian MacLusky, MD, FRCP(C) (Director); Joe Reisman, MD, FRCP(C), MBA (Director, 1996-1999); Henry Levison, MD, FRCP(C) (Director, 1992-1996); Anita Hall, RN (Coordinator). Jennifer Chay; Melody Miki, RN, BScN; Renée Sananes, PhD. Yola Benedet (1994-1999); Susan Carpenter, RN (1998-2001); Michelle Collinson, RN (1994-1998); Jane Finlayson-Kulchin, RN (1994-1998); Kenneth Gore, MA (1993-1999); Noreen Holmes, RRT (1998-1999); Sharon Klassen, MA (1999-2000); José Quenneville, MSc (1993-1995); Christine Wasson, PhD (1999).

Johns Hopkins Asthma and Allergy Center, Baltimore, Md: N. Franklin Adkinson, Jr, MD (Director); Peyton Eggleston, MD (Co-Director); Elizabeth H. Aylward, PhD; Karen Huss, DNSc (Co-Investigator); Leslie Plotnick, MD (Co-Investigator); Margaret Pulsifer, PhD (Co-Investigator); Cynthia Rand, PhD (Co-Investigator); Nancy Bollers, RN (Coordinator). Deborah Bull, LPN; Robert Hamilton, PhD; Kimberly Hyatt; Susan Limb, MD; Mildred Pessaro; Stephanie Philips, RN; Barbara Wheeler, RN, BSN.

National Jewish Medical and Research Center, Denver, Colo: Stanley Szefer, MD (Director); Harold S. Nelson, MD (Co-Director); Bruce Bender, PhD (Co-Investigator); Ronina Covar, MD (Co-Investigator); Andrew Liu, MD (Co-Investigator); Joseph Spahn, MD (Co-Investigator); D Sundström (Coordinator). Melanie Phillips; Michael P. White. Kristin Brelsford (1997-1999); Jessyca Bridges (1995-1997); Jody Ciacco (1993-1996); Michael Eltz (1994-1995); Jeryl Feeley, MA (Coordinator, 1992-1995); Michael Flynn (1995-1996); Melanie Gleason, PA-C (1992-1999); Tara Junk-Blanchard (1997-2000); Joseph Hassell (1992-1998); Marcia Hefner (1992-1994); Caroline Hendrickson, RN (1995-1998; Coordinator, 1995-1997); Daniel Hettleman, MA (1995-1996); Charles G. Irvin, PhD (1992-1998); Jeffrey Jacobs, MD (1996-1997); Alan Kamada, PharmD (1994-1997); Sai Nimmagadda, MD (1993-1996); Kendra Sandoval (1995-1997); Jessica Sheridan (1994-1995); Trella Washington (1993-1997); Eric Willcutt, MA (1996-1997). We also thank the pediatric allergy and immunology fellows for their participation (Kirstin Carel, MD; Neal Jain, MD; Harvey Leo, MD; Beth Macomber, MD; Chris Mjaanes, MD; Lora Stewart, MD; Ben Song, MD).

University of California, San Diego and Kaiser Permanente Southern California Region, San Diego, Calif: Robert S. Zeiger, MD, PhD (Director); Noah Friedman, MD (Co-Investigator); Michael H. Mellon, MD (Co-Investigator); Michael Schatz, MD (Co-Investigator); Kathleen Harden, RN (Coordinator). Elaine M. Jenson; Serena Panzlau; Eva Rodriguez, RRT. James G. Easton, MD (Co-Director, 1993-1994); M. Feinberg (1997-1998); Linda L. Galbreath (1991-2002); Jennifer Gulczynski (1998-1999); Ellen Hansen (1995-1997); Al Jalowayski, PhD (Co-Investigator, 1991-2005); Alan Lincoln, PhD (Co-Investigator, 1991-2003); Jennie

Kaufman (1994); Shirley King, MSW (1992-1999); Brian Lopez (1997-1998); Michaela Magiari-Ene, MA (1994-1998); Kathleen Mostafa, RN (1994-1995); Avraham Moscona (1994-1996); Catherine A. Nelle, RN (1991-2005); Jennifer Powers (2001-2003); Karen Sandoval (1995-1996); Nevin W. Wilson, MD (Co-Director, 1991-1993).

University of New Mexico, Albuquerque, NM: H. William Kelly, PharmD (Director); Aaron Jacobs (Co-Investigator); Mary Spicher, RN (Coordinator). Hengameh H. Raissy. Robert Annett, PhD (Co-Investigator, 1993-2004); Teresa Archibeque (1994-1999); Naim Bashir, MD (Co-Investigator, 1998-2005); H. Selda Bereket (1995-1998); Marisa Braun (1996-1999); Shannon Bush (2002-2006); Michael Clayton, MD (Co-Investigator, 1999-2001); Angel Colon-Semidey, MD (Co-Investigator, 1997-2000); Sara Devault (1993-1997); Roni Grad, MD (Co-Investigator, 1993-1995); David Hunt, RRT (1995-2004); Jeanne Larsson, RN (1995-1996); Sandra McClelland, RN (Coordinator, 1993-1995); Bennie McWilliams, MD (Co-Investigator, Director, 1992-1998); Elisha Montoya (1997-2000); Margaret Moreshead (1996-1999); Shirley Murphy, MD (Co-Investigator, 1992-1994); Barbara Ortega, RRT (1993-1999); David Weers (1997-1998); Jose Zayas (1995-1996).

Washington University, St Louis, Mo: Robert C. Strunk, MD (Director); Leonard Bacharier, MD (Co-Investigator); Gordon R. Bloomberg, MD (Co-Investigator); James M. Corry, MD (Co-Investigator); Denise Rodgers, RFPT (Coordinator). Lila Kertz, MSN, RN, CPNP; Valerie Morgan, RRT; Tina Oliver-Welker, CRTT; Deborah K. White, RPFT, RRT.

Resource centers

Chair's Office, National Jewish Medical and Research Center, Denver, Colo: Reuben Cherniack, MD (Study Chair).

Coordinating Center, Johns Hopkins University, Baltimore, Md: James Tonascia, PhD (Director); Curtis Meinert, PhD (Co-Director). Patricia Belt; Karen Collins; Betty Collison; Ryan Colvin, MPH; John Dodge; Michele Donithan, MHS; Judith Harle; Rosetta Jackson; Hope Livingston; Jill Meinert; Kapreena Owens; Michael Smith; Alice Sternberg, ScM; Mark Van Natta, MHS; Margaret Wild; Laura Wilson, ScM; Robert Wise, MD; Katherine Yates, ScM.

Project Office, National Heart, Lung, and Blood Institute, Bethesda, Md: Virginia Taggart, MPH (Project Officer); Lois Eggers; James Kiley, PhD; Gang Zheng, PhD. Paul Albert, PhD (1991-1999); Suzanne Hurd, PhD (1991-1999); Sydney Parker, PhD (1991-1994); Pamela Randall (1992-2003); Margaret Wu, PhD (1991-2001).

Committees

Data and Safety Monitoring Board: Howard Eigen, MD (Chair); Michelle Cloutier, MD; John Connnett, PhD; Leona Cuttler, MD; David Evans, PhD; Meyer Kattan, MD; Rogelio Menendez, MD; F. Estelle R. Simons, MD. Clarence E. Davis, PhD (1993-2003); Sanford Leikin, MD (1993-1999).

Executive Committee: Reuben Cherniack, MD (Chair); Robert Strunk, MD; Stanley Szefer, MD; Virginia Taggart, MPH; James Tonascia, PhD. Curtis Meinert, PhD (1992-2003).

Steering Committee: Reuben Cherniack, MD (Chair); Robert Strunk, MD (Vice-Chair); N. Franklin Adkinson, MD; Robert Annett, PhD (1992-1995, 1997-1999); Bruce Bender, PhD (1992-1994, 1997-1999); Mary Caesar, MHS (1994-1996); Thomas R. DuHamel, PhD (1992-1994, 1996-1999); H. William Kelly,

PharmD; Henry Levison, MD (1992-1996); Alan Lincoln, PhD (1994-1995); Ian MacLusky, MD; Bennie McWilliams, MD (1992-1998); Curtis L. Meinert, PhD; Sydney Parker, PhD (1991-1994); Joe Reisman, MD, FRCP(C), MBA (1991-1999); Denise Rodgers (2003-2005); Kay Seligsohn, PhD (1996-1997); Gail G. Shapiro, MD; Marian Sharpe (1993-1994); D Sundström (1998-1999); Stanley Szefer, MD; Virginia Taggart, MPH; Martha Tata, RN (1996-1998); James Tonascia, PhD; Scott Weiss, MD, MS; Barbara Wheeler, RN, BSN (1993-1994); Robert Wise, MD; Robert Zeiger, MD, PhD.

Key messages

- *In utero* smoke exposure has been associated with increased prevalence of asthma and reduced lung function in healthy children. There are few data about the impact of IUS on lung function of children diagnosed with asthma.
- *In utero* smoke exposure is associated with less of an improvement in airway responsiveness over time among children with asthma.
- *In utero* smoke exposure may attenuate the beneficial effect of ICSs among children with asthma.

REFERENCES

- DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children's health. *Pediatrics* 2004;113:1007-15.
- Hofhuis W, de Jongste JC, Merkus PJ. Adverse health effects of prenatal and postnatal tobacco smoke exposure on children. *Arch Dis Child* 2003;88:1086-90.
- Hanrahan JP, Tager IB, Segal MR, Tosteson TD, Castile RG, Van Vunakis H, et al. The effect of maternal smoking during pregnancy on early infant lung function. *Am Rev Respir Dis* 1992;145:1129-35.
- Stick SM, Burton PR, Gurrin L, Sly PD, LeSouef PN. Effects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. *Lancet* 1996;348:1060-4.
- Lodrup Carlsen KC, Jaakkola JJ, Nafstad P, Carlsen KH. In utero exposure to cigarette smoking influences lung function at birth. *Eur Respir J* 1997;10:1774-9.
- Gilliland FD, Berhane K, McConnell R, Gauderman WJ, Vora H, Rappaport EB, et al. Maternal smoking during pregnancy, environmental tobacco smoke exposure and childhood lung function. *Thorax* 2000;55:271-6.
- Moshhammer H, Hoek G, Luttmann-Gibson H, Neuberger MA, Antova T, Gehring U, et al. Parental smoking and lung function in children: an international study. *Am J Respir Crit Care Med* 2006;173:1255-63.
- Lannero E, Wickman M, Pershagen G, Nordvall L. Maternal smoking during pregnancy increases the risk of recurrent wheezing during the first years of life (BAMSE). *Respir Res* 2006;7:3.
- Gilliland FD, Li YF, Peters JM. Effects of maternal smoking during pregnancy and environmental tobacco smoke on asthma and wheezing in children. *Am J Respir Crit Care Med* 2001;163:429-36.
- Pattenden S, Antova T, Neuberger M, Nikiforov B, De Sario M, Grize L, et al. Parental smoking and children's respiratory health: independent effects of prenatal and postnatal exposure. *Tob Control* 2006;15:294-301.
- Jaakkola JJ, Kosheleva AA, Katsnelson BA, Kuzmin SV, Privalova LI, Spengler JD. Prenatal and postnatal tobacco smoke exposure and respiratory health in Russian children. *Respir Res* 2006;7:48.
- Skorge TD, Eagan TM, Eide GE, Gulsvik A, Bakke PS. The adult incidence of asthma and respiratory symptoms by passive smoking in uterus or in childhood. *Am J Respir Crit Care Med* 2005;172:61-6.
- Gilliland FD, Berhane K, Li YF, Rappaport EB, Peters JM. Effects of early onset asthma and in utero exposure to maternal smoking on childhood lung function. *Am J Respir Crit Care Med* 2003;167:917-24.
- Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. *N Engl J Med* 2000;343:1054-63.
- The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group. *Control Clin Trials* 1999;20:91-120.
- Weiss ST, Van Natta ML, Zeiger RS. Relationship between increased airway responsiveness and asthma severity in the childhood asthma management program. *Am J Respir Crit Care Med* 2000;162:50-6.
- Raby BA, Van Steen K, Celedon JC, Litonjua AA, Lange C, Weiss ST. Paternal history of asthma and airway responsiveness in children with asthma. *Am J Respir Crit Care Med* 2005;172:552-8.
- Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. *J Allergy Clin Immunol* 2007;120:S94-138.
- Zeiger RS, Szefer SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. *J Allergy Clin Immunol* 2006;117:45-52.
- Szefer SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. *J Allergy Clin Immunol* 2002;109:410-8.
- Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. *Hum Mol Genet* 2004;13:1353-9.
- Sekhon HS, Proskocil BJ, Clark JA, Spindel ER. Prenatal nicotine exposure increases connective tissue expression in foetal monkey pulmonary vessels. *Eur Respir J* 2004;23:906-15.
- Sekhon HS, Keller JA, Benowitz NL, Spindel ER. Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. *Am J Respir Crit Care Med* 2001;164:989-94.
- Sekhon HS, Jia Y, Raab R, Kuryatov A, Pankow JF, Whitsett JA, et al. Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys. *J Clin Invest* 1999;103:637-47.
- Wongtrakool C, Roser-Page S, Rivera HN, Roman J. Nicotine alters lung branching morphogenesis through the alpha7 nicotinic acetylcholine receptor. *Am J Physiol Lung Cell Mol Physiol* 2007;293:L611-8.
- Elliot J, Vullermin P, Robinson P. Maternal cigarette smoking is associated with increased inner airway wall thickness in children who die from sudden infant death syndrome. *Am J Respir Crit Care Med* 1998;158:802-6.
- Elliot JG, Carroll NG, James AL, Robinson PJ. Airway alveolar attachment points and exposure to cigarette smoke in utero. *Am J Respir Crit Care Med* 2003;167:45-9.
- Saetta M, Ghezzi H, Kim WD, King M, Angus GE, Wang NS, et al. Loss of alveolar attachments in smokers: a morphometric correlate of lung function impairment. *Am Rev Respir Dis* 1985;132:894-900.
- Singh SP, Barrett EG, Kalra R, Razani-Boroujerdi S, Langley RJ, Kurup V, et al. Prenatal cigarette smoke decreases lung cAMP and increases airway hyperresponsiveness. *Am J Respir Crit Care Med* 2003;168:342-7.
- Piedimonte G. Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link. *Respir Res* 2002;3(suppl 1):S21-5.
- Gern JE, Rosenthal LA, Sorkness RL, Lemanske RF Jr. Effects of viral respiratory infections on lung development and childhood asthma. *J Allergy Clin Immunol* 2005;115:668-74; quiz 75.
- Wagenknecht LE, Burke GL, Perkins LL, Haley NJ, Friedman GD. Misclassification of smoking status in the CARDIA study: a comparison of self-report with serum cotinine levels. *Am J Public Health* 1992;82:33-6.
- Pickett KE, Rathouz PJ, Kasza K, Wakschlag LS, Wright R. Self-reported smoking, cotinine levels, and patterns of smoking in pregnancy. *Paediatr Perinat Epidemiol* 2005;19:368-76.
- Klebanoff MA, Levine RJ, Morris CD, Hauth JC, Sibai BM, Ben Curet L, et al. Accuracy of self-reported cigarette smoking among pregnant women in the 1990s. *Paediatr Perinat Epidemiol* 2001;15:140-3.
- Christensen AE, Tobiassen M, Jensen TK, Wielandt H, Bakkeiteig L, Host A. Repeated validation of parental self-reported smoking during pregnancy and infancy: a prospective cohort study of infants at high risk for allergy development. *Paediatr Perinat Epidemiol* 2004;18:73-9.
- England LJ, Grauman A, Qian C, Wilkins DG, Schisterman EF, Yu KF, et al. Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes. *Nicotine Tob Res* 2007;9:1005-13.
- Parna K, Rahu M, Youngman LD, Rahu K, Nygard-Kibur M, Koupil I. Self-reported and serum cotinine-validated smoking in pregnant women in Estonia. *Matern Child Health J* 2005;9:385-92.
- Jedrychowski W, Whyatt RM, Cooper TB, Flak E, Perera FP. Exposure misclassification error in studies on prenatal effects of tobacco smoking in pregnancy and the birth weight of children. *J Expo Anal Environ Epidemiol* 1998;8:347-57.